Evidence map›Paper›PMID 37051755›Full record

ArticleESC heart failure2023

Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure.

Emmanuelle Berthelot, Amaury Broussier, Luc Hittinger, Cristiano Donadio, Xavier Rovani, Emmanuel Salengro, Richard Megbemado, Christian Godreuil, Joel Belmin, Jean Philippe David and 3 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Prognostic value of circulating glypican-4 in chronic heart failure.Journal of molecular medicine (Berlin, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Emmanuelle BerthelotUniversité Paris Sud, Paris, France.ORCID 0000-0002-0418-3110
Amaury BroussierDepartment of Geriatrics, AP-HP, Henri-Mondor/Emile-Roux Hospitals, Paris, France.
Luc HittingerDepartment of Cardiology, Heart Failure and Amyloidosis Unit, Referral Center For Cardiac Amyloidosis, Université Paris Est, AP-HP, Henri-Mondor/Albert-Chenevier Hospitals, Paris, France.
Cristiano DonadioDepartment of Geriatrics, AP-HP, Hôpital Charles Foix and Sorbonne Université, Paris, France.
Xavier RovaniHopital Privé Paul Dégine, Paris, France.
Emmanuel SalengroCentre Hospitalier de Villeneuve St Georges, Paris, France.
Richard MegbemadoHôpital Sainte Camille, Paris, France.
Christian GodreuilHôpital d'Instruction des Armées Bégin, Paris, France.
Joel BelminDepartment of Geriatrics, AP-HP, Hôpital Charles Foix and Sorbonne Université, Paris, France.
Jean Philippe DavidDepartment of Geriatrics, AP-HP, Henri-Mondor/Emile-Roux Hospitals, Paris, France.
Bastien GenetBioStatistics Unit, AP-HP, Paris, France.
Thibaud DamyDepartment of Cardiology, Heart Failure and Amyloidosis Unit, Referral Center For Cardiac Amyloidosis, Université Paris Est, AP-HP, Henri-Mondor/Albert-Chenevier Hospitals, Paris, France.
FINC-94 Network
Assistance Publique – Hôpitaux de Paris · FRInserm · FRSorbonne Université · FRCentre Hospitalier Intercommunal de Villeneuve-Saint-Georges · FRHôpital d'Instruction des Armées Bégin · FRHôpital Privé Jacques Cartier · FRHôpital Saint- Camille · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCardiac amyloidosis (CA) is an under-diagnosed cause of heart failure (HF) and has a worse prognosis than other forms of HF. The frequency of death or rehospitalization following discharge for acute heart failure (AHF) in CA (relative to other causes) has not been documented. The study aims to compare hospital readmission and death rates 90 days after discharge for AHF in patients with vs. without CA and to identify risk factors associated with these events in each group. METHODS AND

resultsPatients with HF and CA (HF + CA+) were recruited from the ICREX cohort, after screening of their medical records. The cases were matched 1:5 by sex and age with control HF patients without CA (HF + CA-). There were 27 HF + CA + and 135 HF + CA- patients from the ICREX cohort included in the study. Relative to the HF + CA- group, HF + CA+ patients had a higher heart rate (P = 0.002) and N-terminal prohormone of brain natriuretic peptide levels (P < 0.001) and lower blood pressure (P < 0.001), weight, and body mass index values (P < 0.001) on discharge. Ninety days after discharge, the HF + CA+ group displayed a higher death rate, a higher all-cause hospital readmission rate, and a higher hospital readmission rate for AHF. Death and hospital readmissions occurred sooner after discharge in the HF + CA+ group than in the HF + CA- group.

conclusionsThe presence of CA in patients with HF was associated with a three-fold greater risk of death and a two-fold greater risk of all-cause hospital readmission 90 days after discharge. These findings emphasize the importance of close, active management of patients with CA and AHF.

Indexed as

AmyloidosisHeart FailureHumansPatient DischargePatient ReadmissionPrognosisAcute heart failureCardiac amyloidosisPrognosisStratification

Identifiers

PMID37051755
PMCPMC10192232
OpenAlexW4365443251

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.